Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Research Study with Stanford Medicine

aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
April 30, 2024 06:05 ET | Source: IN8bio, Inc

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
September 22, 2023 08:54 ET | Source: The Insight Partners

Glioma Treatment Market worth $8.29 Billion by 2030 - Exclusive Report by The Insight Partners

Pune, India, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Glioma is a condition that covers a broad category of brain and spinal cord tumors that concern the glial cells in the brain function and can be fatal...
November 15, 2022 06:00 ET | Source: RadioMedix Inc.

RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH

Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory...
October 07, 2022 08:00 ET | Source: CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM

LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for...
July 26, 2022 07:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)...
October 19, 2021 18:12 ET | Source: Telix Pharmaceuticals Limited

IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting

MELBOURNE, Australia and INDIANAPOLIS, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the first set of peer-reviewed results...
August 17, 2021 09:25 ET | Source: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction

A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) --...
January 13, 2021 08:30 ET | Source: InvestorBrandNetwork (IBN)

InvestorBrandNetwork Announces C3 Chat Show Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco

LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
December 28, 2020 08:00 ET | Source: CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary...